Delphi Diagnostics to Present Groundbreaking Endocrine Activity Index at Major Breast Cancer Symposium

Delphi Diagnostics to Present at San Antonio Breast Cancer Symposium

Delphi Diagnostics Inc., a company focused on breast cancer diagnostics, has announced the presentation of four significant scientific abstracts during the upcoming San Antonio Breast Cancer Symposium (SABCS) scheduled for December 9th-11th, 2025 in San Antonio, Texas. Among these abstracts is a key platform presentation detailing new clinical data supporting their innovative Endocrine Activity Index (EAI™), also referred to as the Sensitivity to Endocrine Therapy (SET) Test.

SABCS is recognized as the largest breast cancer research gathering globally, expected to attract over 10,000 attendees from more than 100 countries. This year's gathering promises to be particularly significant for Delphi, as their research gains traction within the scientific community. The company aims to shed light on its groundbreaking EAI, which has potential implications for optimizing treatment decisions in patients diagnosed with hormone receptor-positive, HER2-negative breast cancer.

Key Presentations and Findings

The abstracts being presented at SABCS include:
1. GS3-05: This study evaluates the SET assay's effectiveness in predicting benefits from extended endocrine therapy based on data from the NRG/NSABP B-42 trial. The oral presentation is set for Friday, December 12th, 2025.
2. PS2-07-23: A presentation highlighting predictive markers for distant recurrence found in hormone receptor-positive breast cancer patients undergoing randomized chemotherapy regimens based on the PACS-01 trial.
3. PS3-08-13: This abstract explores the benefits of palbociclib in the PALLAS trial, analyzed through the SET index and prior chemotherapy regimens.
4. PS3-09-21: The study examines the SET as a prognostic biomarker among participants in the Latin American Breast Cancer Cohort Study.

Federico A. Monzon, MD, Chief Medical Officer at Delphi Diagnostics, commented on the significance of the data: "The studies reinforce the endocrine activity pathway's critical role in treatment decision-making. The choice of the NRG/NSABP B-42 trial for a general session oral presentation highlights the importance of our findings."

The EAI test is valuable for assessing the endocrine activity of breast tumors and is particularly designed for stage II-III, hormone receptor-positive, HER2-negative breast cancer patients. Its Index Score incorporates molecular subtype data and clinical factors to refine patient prognosis, thereby aiding in personalized treatment plans. Numerous studies have recognized the EAI as a reliable prognostic indicator, independent of other tests.

Commitment to Advancing Breast Cancer Treatment

Delphi Diagnostics is dedicated to enhancing patient care through scientifically-backed diagnostics. The company's partnership with the University of Texas MD Anderson Cancer Center enables it to commercialize the EAI technology, which was developed in the lab of Dr. W. Fraser Symmans. Delphi’s ultimate goal is to provide the EAI test to patients, paving the way for tailored treatment options that correspond with each patient's unique condition.

With these advancements, Delphi Diagnostics is not only contributing to the field of breast cancer diagnostics but also reinforcing the importance of individualized treatment approaches. As the SABCS approaches, the international community anticipates significant insights from Delphi’s presentations, aimed at benefiting patients and the broader medical community.

To stay updated and learn more about Delphi Diagnostics and the Endocrine Activity Index, visit www.delphi-diagnostics.com.